Status:
COMPLETED
An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Hypertension
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
To assess the long term safety and efficacy of telmisartan plus amlodipine FDC in patients with essential hypertension who failed to control their BP with either monotherapy
Eligibility Criteria
Inclusion
- Patients with essential hypertension
- Outpatient
Exclusion
- Patients whose SBP \>=180 mmHg or DBP \>=110 mmHg at the end of treatment visit of the double-blind treatment period in the "non-responder trials"
- Patients who have met any of the exclusion criteria defined in the "non-responder trials"
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
259 Patients enrolled
Trial Details
Trial ID
NCT00618774
Start Date
January 1 2008
Last Update
June 27 2014
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
1235.16.004 Boehringer Ingelheim Investigational Site
Chofu, Tokyo, Japan
2
1235.16.006 Boehringer Ingelheim Investigational Site
Nishi-ku, Hiroshima, Hiroshima, Japan
3
1235.16.005 Boehringer Ingelheim Investigational Site
Osaka, Osaka, Japan
4
1235.16.007 Boehringer Ingelheim Investigational Site
Osaka, Osaka, Japan